ArticleScientific reports2025
A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent case reports linked use of the lipid-lowering class of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to severe hypersensitivity reactions. Therefore, our pharmacovigilance study assessed the association between reporting of PCSK9 inhibitors and hypersensitivity or anaphylaxis. We analyzed the US Food and Drug Administration Adverse Event Reporting System (FAERS) extracting spontaneous reports from 2015 to 2023. We calculated reporting odds ratios (ROR), proportional reporting ratios, and information components (IC) as measures of disproportionate reporting of hypersensitivity or anaphylaxis with PCSK9 inhibitors overall and with specific compounds (alirocumab, evolocumab) using the entire FAERS as comparator. In sensitivity analyses, we adjusted for demographic characteristics, used statins as active comparator, and applied alternate outcome definitions. Among all reports in FAERS during the study period involving PCSK9 inhibitors, we identified 12,591 cases of hypersensitivity and 17,214 cases of anaphylaxis. Across disproportionality analysis methods, we did not observe an association between the reporting of PCSK9 inhibitors or evolocumab specifically and the outcomes. However, there were associations with alirocumab and hypersensitivity (ROR, 1.14; 95% confidence interval [CI], 1.11-1.18 / IC, 0.19; 95% credible interval [CrI], 0.14-0.24) and with alirocumab and anaphylaxis (ROR, 1.30; 95% CI, 1.26-1.33; IC, 0.37; 95% CrI, 0.33-0.42). Sensitivity analyses corroborated the lack of an association with PCSK9 inhibitors or with evolocumab and were inconsistent regarding alirocumab. Our large pharmacovigilance study showed no signal of disproportionate reporting for hypersensitivity or anaphylaxis with PCSK9 inhibitors overall. The inconsistencies in alirocumab related findings argue against a compound specific signal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.